Search | Clinical Trials Finder

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Garetosmab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • Nashville, Tennessee

Conditions: Stroke, Ischemic, Pain, Postoperative, Substance Abuse, Subarachnoid Hemorrhage
Interventions: Placebo, NP10679; Drug
Lead sponsor: Neurop Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain
Interventions: J-Tip jet injector, Jet injection saline, lidocaine cream; Device · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Years to 21 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Liberty Township, Ohio

Conditions: Healthy Participants
Interventions: BOS161721, Placebo; Drug
Lead sponsor: Boston Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive
Interventions: GIK, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 13
States / cities: Anchorage, Alaska • New Haven, Connecticut • Macon, Georgia + 10 more

Conditions: Malignant Neoplasm
Interventions: placebo administration, EMLA, propofol, fentanyl citrate; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 22 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Multiple Myeloma
Interventions: Ramantamig, Tocilizumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more

Conditions: Acute Kidney Injury
Interventions: Iopamidol 300 (Contrast), Placebo (Normal Saline); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hematologic Diseases, Anemia, Sickle Cell
Interventions: Intravenous Ketorolac, Ibuprofen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions: Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: INBRX-106, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 22 more

Conditions: Healthy
Interventions: Single-Dose IV Oritavancin Diphosphate, Placebo, Moxifloxacin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Tonsillectomy
Interventions: Intravenous ibuprofen, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Louisville, Kentucky • Newark, New Jersey • Charlotte, North Carolina + 3 more

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opiate Addiction
Interventions: 6β-Naltrexol escalating doses from 0.05-0.5 mg IV; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
Interventions: OCE-205, Placebo; Drug
Lead sponsor: Ocelot Bio, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more

Conditions: Stroke, Cerebral Ischemia, Brain Infarction
Interventions: Ancrod (Viprinex), Placebo; Drug
Lead sponsor: Neurobiological Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 58
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Loma Linda, California + 48 more

Conditions: Alzheimer's Disease
Interventions: TB006, Placebo; Drug
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Garden Grove, California • San Diego, California • Delray Beach, Florida + 10 more

Conditions: Idiopathic Hypersomnia
Interventions: TAK-925, TAK-925 Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 20
States / cities: Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 17 more

Conditions: Respiratory Distress Syndrome, Acute
Interventions: GEn-1124, Placebo; Drug
Lead sponsor: GEn1E Lifesciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Washington D.C., District of Columbia • Kansas City, Kansas • Baltimore, Maryland + 8 more

Conditions: Symptomatic Uterine Fibroids and Adenomyosis
Interventions: IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 80
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more

Conditions: Acute Myeloid Leukemias
Interventions: Revumenib, Placebo, Intensive Chemotherapy Regimen; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 6
States / cities: Goodyear, Arizona • Duarte, California • Indianapolis, Indiana + 3 more

Search by objective public record fields.

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.

Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Double-Blind Placebo-Controlled CIN Trial

Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation